



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: 15270J-004747US

Dale B. SCHENK

Appln. No.: 10/828,548

Group Art Unit: 1649

Confirmation No.: 3885

Examiner: Daniel E. Kolker

Filed: April 19, 2004

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

COPY CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited on August 18, 2006 with the United States Postal Service in an envelope as "Express Mail Post Office To Addressee," mailing label No. EV 843 554 953 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

8/18/06

Lili Maddatu
Lili Maddatu

Date

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of references 588-618 and 620-641 can be found in Application No. 09/322,289, filed May 28, 1999 (Attorney Docket No. 15270J-004740US). Copies of references 648-655, 662-666, 676-678, 681-682, 687-690, 694-701, 727-729, 731-739, 741-746, 749-757, 759, 765-769, and 772-775 are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicants note that an opposition has been filed against European application, EP 0 568 575. EP 0 568 575 is a commonly owned application directed to related subject matter and corresponding to US Application Nos. 09/204,838 filed 12/03/98, 09/724,921 filed

08/22/2006 MBLANCO 00000008 194880 10828548
01 FCT 1806 100.00 DA

Application No. 10/828,548

Supplemental Information Disclosure Statement filed August 18, 2006

11/28/00; and, 09/724,929 filed 11/28/00, which are now abandoned (all of record). References D1-D2, D5-D6, D10-D11, and D19-D21 cited in the opposition are being made of record and are identified on the attached PTO/SB/08A and PTO/SB/08B forms as references 760-763 and 765-769, respectively. Other references cited in the opposition are already of record. All papers in the opposition can be viewed online at the European Patent Office at <http://www.epoline.org/portal/public/registerplus> or can be provided on request. The opposition is still in progress.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98; issued as U.S. 6,787,523 on 09/07/04;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00; issued as U.S. 6,787,143 on 09/07/04;
09/723,927 filed 11/28/00; issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00; issued as U.S. 6,787,144 on 09/07/04 ;
09/724,102 filed 11/28/00; issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00; issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04; issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04; issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04; issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
11/108,102 filed 04/15/05;
11/245,524 filed 10/07/05;
10/934,609 filed 09/02/04; issued as U.S. 6,946,135 on 09/20/2005;
11/245,916 filed 10/7/05;
10/933,559 filed 09/02/04; issued as U.S. 6,972,127 on 12/06/05;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04; issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04; issue fee paid 01/24/05;
10/815,404 filed 03/31/04; issued as U.S. 6,982,084 on 01/03/06;

Application No. 10/828,548
Supplemental Information Disclosure Statement filed August 18, 2006

10/884,892 filed 07/01/04; issued as U.S. 6,962,707 on 11/08/05;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00; issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04; 
10/923,605 filed 08/20/04;
10/923,267 filed 08/20/04;
10/923,469 filed 08/20/04;
09/724,940 filed 11/28/00; issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00; issued as U.S. 6,743,427 on 6/1/04;
10/823,463 filed 04/12/04;
11/058,757 filed 02/14/05;
11/396,391 filed 03/30/06;
09/580,018 filed 05/26/00; issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00; issued as U.S. 6,750,324 on 6/15/04;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00; issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,024 filed 04/12/04;
10/889,999 filed 04/12/04;

Application No. 10/828,548
Supplemental Information Disclosure Statement filed August 18, 2006

10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/723,765 filed 11/28/00;
10/822,968 filed 04/12/04;
09/724,567 filed 11/28/00; issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00; issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00; issued as U.S. 6,936,246 on 08/30/05;
09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed
05/26/00); and,

09/979,952 filed 04/09/02 (U.S. National Stage of PCT/US00/15239 filed
06/01/00); issued as U.S. 6,913,745 on 07/05/05.

Applicant also cites the following copending applications directed to related
subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/789,273 filed 2/27/04;
10/232,030 filed 08/30/02;
10/388,389 filed 03/12/03;
10/703,713 filed 11/07/03;
10/704,070 filed 11/07/03;
_____ filed 03/30/06;
10/388,214 filed 03/12/03;
10/858,855 filed 06/01/04;
10/771,174 filed 02/04/04;
11/260,047 filed 10/26/05;
11/304,986 filed 12/15/05;
11/305,889 filed 12/15/05;
60/637,253 filed 12/16/04;

Application No. 10/828,548
Supplemental Information Disclosure Statement filed August 18, 2006

11/305,899 filed 12/15/05;
11/303,478 filed 12/15/05;
11/304,072 filed 12/15/05;
60/736,119 filed 11/10/05;
60/691,821 filed 06/17/05;
60/735,687 filed 11/10/05;
10/544,093 filed 08/01/05 (U.S. National Stage of PCT/US04/02856 filed 01/31/04);
_____ filed 11/10/05;
_____ filed 11/10/05; and
_____ filed 01/27/06;
11/342,353 filed 01/27/06.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
09/580,015 filed 05/26/00;
09/580,019 filed 05/26/00;
09/724,291 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed 06/01/00);
09/579,690 filed 05/26/00;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;

Application No. 10/828,548
Supplemental Information Disclosure Statement filed August 18, 2006

09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99, and
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;
60/444,150 filed 02/01/03;
60/616,474 filed 10/05/04;
60/622,525 filed 10/26/04;
60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04;
60/736,045 filed 11/10/05;
60/648,631 filed 01/28/05;
60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03; and
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Application No. 10/828,548
Supplemental Information Disclosure Statement filed August 18, 2006

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she are invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 19-4880. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Rosemarie L. Celli
Registration No. 42,397

SUGHRUE MION, PLLC
Telephone: (650) 625-8100
Facsimile: (650) 625-8110

MOUNTAIN VIEW OFFICE
23493
CUSTOMER NUMBER

Date: August 18, 2006
44628_1.DOC



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 10

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.

Attorney Docket Number

15270J-004747US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	686	6,972,127	12-06-2005	Schenk	
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	693	2005/0191314 A1	09-01-2005	Schenk	
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	685	2005/0163788 A1	07-28-2005	Schenk	
	657	6,913,745	07-05-2005	Schenk	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	658	6,905,686	06-14-2005	Schenk	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	659	6,890,535	05-10-2005	Schenk	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	661	2005/0009150 A1	01-13-2005	Basi et al.	
	673	6,808,712	10-26-2004	Schenk	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	675	6,710,226	02-23-2004	Schenk	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60849503

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.

Attorney Docket Number 15270J-004747US

748	6,610,493	08-26-2003	Citron et al.
730	2003/0166557 A1	09-04-2003	Minna et al.
702	6,548,640	04-15-2003	Winter
725	6,538,124	03-25-2003	Idusogie et al.
726	6,528,624	03-04-2003	Idusogie et al.
710	6,407,213	06-18-2002	Carter et al.
720	6,277,375	08-21-2001	Ward
724	6,194,551	02-27-2001	Idusogie et al.
704	6,180,370	01-30-2001	Queen et al.
747	6,175,057	01-16-2001	Mucke et al.
719	6,165,745	12-26-2000	Ward et al.
723	6,121,022	09-19-2000	Presta et al.
722	5,869,046	02-09-1999	Presta et al.
707	5,859,205	01-12-1999	Adair et al.
770	5,733,548	03-31-1998	Restifo et al.
642	5,702,906	12-30-1997	Rosenthal
643	5,693,762	12-02-1997	Queen et al.
705	5,693,761	12-02-1997	Queen et al.
721	5,677,425	10-14-1997	Bodmer et al.
717	5,648,260	07-15-1997	Winter et al.
718	5,624,821	04-29-1997	Winter et al.
644	5,618,920	04-08-1997	Robinson et al.
764	5,601,827	02-11-1997	Collier et al.
706	5,585,089	12-17-1996	Queen et al.
619	5,530,101	06-25-1996	Queen et al.
645	5,258,498	11-02-1993	Huston et al.
703	5,225,539	07-06-1993	Winter
740	4,883,666	11-28-1989	Sabel et al.
646	4,816,567	03-28-2989	Cabilly et al.
647	4,816,397	03-28-1989	Boss et al.

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60849503

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/828,548
(use as many sheets as necessary)		Filing Date	April 19, 2004
		First Named Inventor	Schenk
		Art Unit	1649
		Examiner Name	Kolker, D. E.
Sheet	3	of	10
		Attorney Docket Number	15270J-004747US

U.S. PATENT APPLICATIONS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	691	11/245,524	10-07-2005	Schenk	
	692	11/245,916	10-07-2005	Schenk	
	763	60/067,740	12-02-1997	Schenk	
	760	60/067,219	12-03-1997	Weiner et al.	
	761	60/079,697	03-27-1998	Weiner et al.	
	762	60/080,970	01-11-1999	Schenk	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	738	EP	626 390	A1	11-30-1994			
	737	EP	620 276	A1	10-19-1994			
*	632	JP	07-132033	A	05-23-1995			abst. only
*	631	JP	62-267297	A	11-19-1987			abst. only
	701	WO	05/014041	A2	02-17-2005			
	757	WO	04/108895	A2, A3	12-16-2004			
	756	WO	03/016467	A2, A3	02-27-2003			
	772	WO	99/10008	A1	03-04-1999			
	633	WO	96/08665	A2	03-21-1996			
	630	WO	95/17085	A1	06-29-1995			
*	696	WO	95/06407	A1	03-09-1995			
*	736	WO	94/10569	A1	05-11-1994			
	648	WO	91/09967	A1	07-11-1991			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60849503

* I FW DID NOT RECEIVE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

11

Complete if Known	
Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.

Attorney Docket Number 15270J-004747US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	
	773	ALBERTS ET AL., <i>Molecular Biology of the Cell, 2nd Edition</i> , pages 266-267, Garland Publishing Inc., New York (1989). /	
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <i>Science</i> , 233:747-753 (1986).	
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <i>Neuroscience Letters</i> , 128(1):126-128 (1991).	
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <i>The Scientist</i> , 18(20):28-29 (2004).	
	677	ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <i>Int. J. Geriatric Psychiatry</i> , 20:101-105 (2005).	
	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	
	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against βA4 Protein: A Potential Probe for Alzheimer's Disease," <i>Bioconjugate Chem.</i> , 5:119-125 (1994).	
	754	BLASBERG et al., "Regional Localization of Glioma-assoicated Antigen Defined by Monoclonal Antibody 81C6 <i>in Vivo</i> : Kinetics and Implications for Diagnosis and Therapy," <i>Cancer Research</i> , 47:4432-4443 (1987). ✓	
	746	BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <i>J. Biol. Chem.</i> , 275(22):16941-16947 (2000). /	
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ---44631-1

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

11

Complete if Known

Application Number **10/828,548**Filing Date **April 19, 2004**First Named Inventor **Schenk**Art Unit **1649**Examiner Name **Kolker, D. E.**Attorney Docket Number **15270J-004747US**

	591	CHROMY et al., "Self-assembly of A β (1-42) into globular neurotoxins," <u>Biochemistry</u> , 42(44):12749-12760 (2003).	
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities," <u>PNAS</u> , 93(23):13170-13175 (1996).	
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <u>Nat. Neurosci.</u> , 5:1055-1057 (2002).	
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <u>J. Neurosci. Res.</u> , 58:120-129 (1999).	
	766	COICO et al., <i>Immunology A Short Course, Fifth Edition</i> , pages 18-24 (2003).	✓
	687	COX et al., "Adjuvants—a classification and review of their modes of action," <u>Vaccine</u> , 15(3):248-256 (1997).	
	769	DAVIS, S. S., "Nasal Vaccines," <u>Advanced Drug Delivery Reviews</u> , 51:21-42 (2001).	
	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <u>Rev. In Neurosciences</u> , 5:213-225 (1994).	
	594	DEMATTOS et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <u>Science</u> , 295(5563):2264-2267 (2002).	
	745	DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <u>Experimental Neurology</u> , 149:329-340 (1998).	
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991).	
	595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002).	
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003).	
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ---44631-1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

11

Complete if Known

Application Number 10/828,548

Filing Date April 19, 2004

First Named Inventor Schenk

Art Unit 1649

Examiner Name Kolker, D. E.

Attorney Docket Number 15270J-004747US

	598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996).	
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003).	
	600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000).	
	650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992).	
	601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003).	
	602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001).	
	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004).	
	634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.	
	635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.	
	636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.	
	637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.	
	604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).	
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).	
	694	GUPTA et al., "Adjuvants for human vaccines--current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995).	
	606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ---44631-1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

11

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.

Attorney Docket Number 15270J-004747US

664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).
741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <i>Int. J. Biochem. & Cell Biol.</i> , 35:1608-1613 (2003).
607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <i>Nat. Med.</i> , 8(11):1270-1275 (2002).
662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Juman Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <i>J. Biol. Chem.</i> , 271(37):22908-22914 (1996).
608	IRIZARRY et al., "Alzheimer disease therapeutics," <i>J. Neuropathol. Exp. Neurol.</i> , 60(10):923-928 (2001).
609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <i>Physiol. Behav.</i> , 73(5):873-886 (2001).
640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <i>J. Neurosci. Res.</i> , 46:336-348 (1996).
729	KASCSEK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <i>J. Virology</i> , 61(12):3688-3693 (1987).
628	KOFLER et al., "Mechanism of Allergic Cross-Reactions--III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <i>Mol. Immunology</i> , 29(2):161-166 (1992).
627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <i>J. Immunol.</i> , 157(6):2430-2439 (1996).
695	KÜO et al., "Water-soluble $\text{A}\beta$ (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <i>J. Biol. Chem.</i> , 271(8):4077-4081 (1996).
734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <i>Appl. Pathol.</i> , 3(1-2):39-54 (1985).
651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <i>J. Immunology</i> , 166(3):1748-1754 (2001).
755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <i>J. Molecular Neuroscience</i> , 24:105-113 (2004).

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ----44631-1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

11

Complete if Known

Application Number 10/828,548

Filing Date April 19, 2004

First Named Inventor Schenk

Art Unit 1649

Examiner Name Kolker, D. E.

Attorney Docket Number 15270J-004747US

	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?", <u>Immunity & Aging</u> , 1:1-2 (2004).	
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).	
	665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).	
	666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).	
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004).	
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).	
	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989).	
	610	MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003).	
	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).	
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002).	
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003).	
	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003).	
	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989).	
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <u>J. Neurosci. Res.</u> , 46(3):283-293 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ---44631-1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 11

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.

Attorney Docket Number 15270J-004747US

	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <u>Biochemistry</u> , 38(12):3570-3578 (1999).	
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <u>PNAS</u> , 85:3080-3084 (1998).	
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <u>Drugs</u> , 53(5):752-768 (1997).	
	653	PAUL, W. E., eds., <u>Fundamental Immunology</u> , Third Edition, pages 292-295, Raven Press, New York (1993).	
	774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunological Methods</u> , 120:133-143 (1989).	/
	616	PFEIFFER et al., "Cerebral hemorrhage after passive anti- $A\beta$ immunotherapy," <u>Science</u> , 298(5597):1379 (2002).	
	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).	
	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α ," <u>PNAS</u> , 92:11294-11298 (1995).	/
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005).	
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	
	655	RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982).	
	617	SCHMID, R. E., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news , pages 1-5 (2002).	
	768	SCHMITT et al., "Interactions of the alzheimer β amyloid fragment ₍₂₅₋₃₅₎ with peripheral blood dendritic cells," <u>Mechanisms of Ageing and Development</u> , 94:223-232 (1997).	/

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ---44631-1

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

10

of

11

Complete if Known

Application Number 10/828,548

Filing Date April 19, 2004

First Named Inventor Schenk

Art Unit 1649

Examiner Name Kolker, D. E.

Attorney Docket Number 15270J-004747US

629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <u>PNAS</u> , 96:2262-2267 (1999).	
618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002).	
622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003).	
697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).	
620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β-amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	
621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	
678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).	
767	TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17(4):541-547 (1996).	
700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <u>Kidney International</u> , 61:907-912 (2002).	
775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995).	✓
690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <u>Drugs Aging</u> , 19(7):487-494 (2002).	
623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	
624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	
676	<i>Webster's New World Dictionary</i> , page 1387, therapeutic (1988).	
688	<i>Webster's New World Dictionary of American English</i> , Third College Edition, page 1078 (1988).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ----44631-1

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 11

Complete if Known	
Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk
Art Unit	1649
Examiner Name	Kolker, D. E.

Attorney Docket Number 15270J-004747US

	765	WEINER, H. L., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases," <u>Immunology Today</u> , 18:335-343 (1997). <input checked="" type="checkbox"/>
	739	WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," <u>Biochemistry</u> , 35(43):13709-13715 (1996). <input type="checkbox"/>
	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003). <input type="checkbox"/>
	749	Wikipedia definition of "epitope" printed from internet on 4/26/06. <input type="checkbox"/>
	752	Wikipedia definition of "antigen" printed from internet on 4/26/06. <input checked="" type="checkbox"/>
	753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06. <input checked="" type="checkbox"/>
	728	YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <u>Scand. J. Immunol.</u> , 46(2):175-179 (1997). <input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60849503 ---44631-1



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/828,548
		Filing Date	April 19, 2004
		First Named Inventor	Schenk, Dale B.
		Art Unit	1649
		Examiner Name	Kolker, Daniel
Total Number of Pages in This Submission	22	Attorney Docket Number	15270J-004747US

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form (1 page, submitted in duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (7 pgs.) with PTO/SB/08A (3 pgs.) and PTO/SB/08B Forms (8 pgs.) and copies of *cite nos. 648-655, 662-666, 676-678, 681-682, 687-690, 694-701, 727-729, 731-739, 741-746, 749-757, 759, 765-769, and 772-775. <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawings Sheets <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Return Receipt Postcard	

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 19-4880.

* Not included in "Total Number of Pages in This Submission"

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Rosemarie L. Celli	Reg. No. 42,397
Signature		
Date	August 18, 2006	

CERTIFICATE OF MAILING

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited on August 18, 2006 with the United States Postal Service in a box as "Express Mail Post Office to Addressee," mailing label No. EV 843 554 953 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed or printed name	Lilli Maddatu	
Signature		Date 8/18/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 44547_1.DOC



AUG 18 2006

PTO/SB/17 (12-04)

Effective on 12/08/2004.

Fee Pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEETRANSMITTAL

For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT **(\$)** **180**

Complete if Known

Application Number	10/828,548
Filing Date	April 19, 2004
First Named Inventor	Schenk, Dale B.
Examiner Name	Kolker, Daniel
Art Unit	1649
Attorney Docket No.	15270J-004747US

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____
 Deposit Account Deposit Account Number: 19-4880 Deposit Account Name: Sughrue Mion, PLLC

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee
 Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

<u>Application Type</u>	<u>FILING FEES</u>		<u>SEARCH FEES</u>		<u>EXAMINATION FEES</u>		
	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Fees Paid (\$)</u>
Utility							
Design							
Plant							
Reissue							
Provisional							

2. EXCESS CLAIM FEES

Fee Description Small Entity
Fee (\$) Fee (\$)

Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent

Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent

Multiple dependent claims

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
-20 or HP =	x	=				

HP = highest number of total claims paid for, if greater than 20

<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
-3 or HP =	x	=			

HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
- 100 =	/ 50 =	(round up to a whole number) x	=	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: 1806 1.17(p) Submission of an Information Disclosure Statement

\$180

SUBMITTED BY

Signature		Registration No. (Attorney/Agent) 42,397	Telephone 650-625-8100
Name (Print/Type)	Rosemarie L. Celli		Date <u>Aug. 18, 2006</u>